Abstract:Abstract Unlimited replicative capacity is a key hallmark of cancer that requires the abrogation of telomere attrition due to the end-replication problem. The vast majority of tumors maintain telomere lengths by expressing the enzyme telomerase; however, a subset utilizes a cancer-specific, telomerase-independent telomere maintenance mechanism, termed Alternative Lengthening of Telomeres (ALT). We recently uncovered a strong correlation between ALT and recurrent cancer-associated somatic inactivating mutations in the ATRX and DAXX genes. The ATRX and DAXX proteins form a chromatin remodeling complex with histone chaperone activity, targeting incorporation of the histone variant H3.3 to G-rich repetitive regions of the genome, including the telomeres, which are known to normally be maintained in a repressed heterochromatic state. Here, we have developed an isogenic cell line pair derived from first generation telomerase knock-out (KO) mouse embryonic fibroblasts. Compared to early-passage telomerase KO cells and late passage WT control cells, late-passage telomerase KO cells spontaneously developed the ALT phenotype. These ALT(+) cells display increased DNA damage, as observed by dramatically increased accumulation of γH2AX foci. We plan to use this unique cell line to identify drugs exhibiting selective toxicity for ALT(+) cells. Preliminary results indicate that ALT(+) late-passage telomerase KO cells exhibit an increased sensitivity to the DNA-PK inhibitor NU7441 compared to the isogenic early-passage ALT(-) telomerase KO cells. The identification of bona fide ALT-specific drugs will pave the way for the development of new targeted treatments for the significant number of cancers that harbor this unique molecular phenotype. Citation Format: Christopher M. Heaphy, Michael C. Haffner, Alan K. Meeker. A novel cell line model of the alternative lengthening of telomeres (ALT) telomere maintenance mechanism. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Jun 19-22, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2013;73(13 Suppl):Abstract nr A06.

Disease mutant analysis identifies a new function of DAXX in telomerase regulation and telomere maintenance.

Cancer-associated DAXX mutations reveal a critical role for ATRX localization in ALT suppression

Negative Regulation of p53 Functions by Daxx and the Involvement of MDM2

DAXX-ATRX regulation of p53 chromatin binding and DNA damage response

ATRX/DAXX: Guarding the Genome Against the Hazards of ALT

Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX

Genomic Footprints of Activated Telomere Maintenance Mechanisms in Cancer

DAXX in cancer: phenomena, processes, mechanisms and regulation

Switch Telomerase to ALT Mechanism by Inducing Telomeric DNA Damages and Dysfunction of ATRX and DAXX.

Akt-Mediated Phosphorylation of XLF Impairs Non-Homologous End-Joining DNA Repair

DAXX, As a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.

Abstract A06: A novel cell line model of the alternative lengthening of telomeres (ALT) telomere maintenance mechanism

Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway

TZAP overexpression induces telomere dysfunction and ALT-like activity in ATRX/DAXX-deficient cells

Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT)

Non‐telomerase telomere maintenance in human cells (97.2)

Alternative Lengthening of Telomeres and Mediated Telomere Synthesis

Opposing biological functions of the cytoplasm and nucleus DAXX modified by SUMO-2/3 in gastric cancer

Alternative Lengthening of Telomeres: DNA Repair Pathways Converge

Phosphorylation of 'SDT-like' motifs in ATRX mediates its interaction with the MRN complex and is important for ALT pathway suppression